Melanoma Margins Trial II - A Phase III, Multi-centre Randomized Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC stage II Primary Cutaneous Melanoma (MelMarT-II)

黑色素瘤边缘试验 II - 一项 III 期、多中心随机对照试验，研究 AJCC II 期原发性皮肤黑色素瘤的 1cm v 2cm 宽手术切除边缘 (MelMarT-II)

• 批准号: 408863
• 负责人: Dancey Janet E
• 金额: $ 94.96万
• 依托单位: Queen's University (Kingston, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2029-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=408863&lang=en
• 关键词: Cancer; Melanoma; Quality Of Life; Randomized Controlled Trial; Surgery; Surgical Morbidity / Complications; Wide Local Excision

The incidence of melanoma is increasing worldwide. In 2019, 7800 Canadians will be diagnosed and 1300 will die from melanoma. Wide local excision (WLE) around the primary melanoma and a sentinel lymph node biopsy is standard treatment. The thickness (or d

黑色素瘤的发病率在世界范围内不断增加。2019年，将有7800名加拿大人被诊断出患有黑色素瘤，1300人将死于黑色素瘤。标准治疗是原发性黑色素瘤周围的广泛局部切除术（WLE）和前哨淋巴结活检。厚度（或d